FierceBiotech

Fierce 15 nominations are now open! We're taking submissions for the most innovative, resourceful and visionary biotechs here ⬇️fiercebiotech.com/biotech/nomina…

Since 2022, China biotechs have developed 639 first-in-class drug candidates, a staggering 360% increase from 137 candidates from 2018 to 2021, according to Jefferies. fiercebiotech.com/biotech/china-…

Days after picking up IGM Biosciences, serial biotech acquirer Concentra has secured another company in the form of cell therapy-focused Cargo Therapeutics. $CRGX fiercebiotech.com/biotech/concen…

AstraZeneca will build a multi-billion manufacturing site in Virginia, says CEO Pascal Soriot at ceremony in D.C.

The FDA has placed a clinical hold across all of Sarepta’s investigational limb girdle muscular dystrophy trials, while also revoking the biopharma’s gene therapy platform technology designation. $SRPT fiercebiotech.com/biotech/sarept…

Roche’s hopes of getting its COPD drug to regulators this year have taken a hit after the anti-ST2 monoclonal antibody failed to reduce flare-ups in a phase 3 study. fiercebiotech.com/biotech/roches…

As 'the most infectious virus' roars back to life, the first measles treatment remains a pipe dream, @FierceBiotech's Darren Incorvaia reports fiercebiotech.com/research/you-j…

Novartis has ended work on ianalumab in a painful skin condition after the monoclonal antibody failed to meet “predefined efficacy thresholds” in a phase 2 study. $NVS fiercebiotech.com/biotech/novart…

Sarepta's stock price surges in postmarket trading after announcing an Elevidys black box warning and a restructure that includes 500 layoffs. “We have chosen not to be complacent,” CEO Douglas Ingram said about the restructure in an investor call. $SRPT fiercebiotech.com/biotech/sarept…

AstraZeneca’s plans to get an amyloidosis drug to market look further out of reach after the pharma’s anti-fibril antibody failed to reduce deaths and hospitalizations in a key phase 3 study. $AZN fiercebiotech.com/biotech/astraz…

AbbVie is paying Ichnos Glenmark Innovation $700M upfront for a next-gen rival to J&J’s Tecvayli, positioning the pharma to advance a new option for multiple myeloma patients. $ABBV fiercebiotech.com/biotech/abbvie…

Merck boosts respiratory portfolio with $10B acquisition of Verona and potential COPD blockbuster Ohtuvayre fiercepharma.com/pharma/merck-s…

Supreme Court reopens floodgates for federal agency mass layoffs, agency restructurings bit.ly/4lGKnL5

Apple Tree Partners’ life sciences venture fund is suing its controlling limited partners, claiming the Rybolovlev family trust has failed to meet its monetary commitments and warning of immediate consequences for its biotech portfolio. fiercebiotech.com/biotech/emerge…

Altimmune’s GLP-1/glucagon dual receptor agonist achieved a hit and a miss when it came to the dual goals of a phase 2 MASH study, while still showcasing the asset’s weight loss potential. $ALT fiercebiotech.com/biotech/altimm…